9 results on '"Wang, Hong-Yang"'
Search Results
2. Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma
- Author
-
Zeng, Jin-Zhang, Wang, Hong-Yang, Chen, Zheng-Jun, Ullrich, Axel, and Wu, Meng-Chao
- Published
- 2002
- Full Text
- View/download PDF
3. Effect of the Standardized Management of Cancer Pain on Patients with Bone Metastasis of Lung Cancer in China.
- Author
-
Jin, Jing-Jing, Xu, Tian-Tian, Li, Yan-Fang, Wang, Hong-Yang, Zhang, Dan, Zhang, Pan-Pan, Xu, Li-Xin, Wang, Chun-Xiu, Fan, Zhu, Wang, Ling, Liu, Chen, Wang, Shuang, Shi, Hao-Tian, Li, Cai-Hong, Zhang, Hai-Fang, and Huang, Yan
- Subjects
BONE metastasis ,LUNG cancer ,PAIN management ,METASTASIS ,CANCER patients - Published
- 2020
- Full Text
- View/download PDF
4. The role of necroptosis in cancer: A double-edged sword?
- Author
-
Qin, Xia, Ma, Dan, Tan, Ye-xiong, Wang, Hong-yang, and Cai, Zhenyu
- Subjects
- *
CELL death , *SWORDS , *CANCER , *CANCER invasiveness , *CANCER treatment - Abstract
Necroptosis is a programmed, caspase-independent cell death that is morphologically similar to necrosis. Unlike apoptosis, necroptosis evokes inflammatory responses by releasing damage-associated molecular patterns. Recent studies suggest that tumor undergoes necroptosis in vivo and necroptosis has pro- or anti-tumoral effects in cancer development and progression. Furthermore, triggering necroptosis in tumor cells has been explored as a potential therapeutic strategy against cancer. Here, we will review the recent research progress of necroptosis in conferring anti- or pro-tumoral effects and its potential application in cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2.
- Author
-
Qin, Chen-Jie, Zhao, Ling-Hao, Zhou, Xu, Zhang, Hui-Lu, Wen, Wen, Tang, Liang, Zeng, Min, Wang, Ming-Da, Fu, Gong-Bo, Huang, Shuai, Huang, Wei-Jian, Yang, Yuan, Bao, Zhi-Jun, Zhou, Wei-Ping, Wang, Hong-Yang, and Yan, He-Xin
- Subjects
- *
IMMUNOSTAINING , *IMMUNOHISTOCHEMISTRY techniques , *GENE expression , *MOLECULAR genetics , *CYTOKINES , *OBESITY complications , *ANIMAL experimentation , *BIOCHEMISTRY , *CELL lines , *CELL physiology , *COMPARATIVE studies , *DIET , *GENES , *HEPATOCELLULAR carcinoma , *INFLAMMATORY mediators , *LIVER tumors , *PHENOMENOLOGY , *RESEARCH methodology , *MEDICAL cooperation , *METASTASIS , *MICE , *OBESITY , *PROGNOSIS , *PROTEOLYTIC enzymes , *RATS , *RESEARCH , *EVALUATION research , *DISEASE progression - Abstract
Obesity is a major risk factor for hepatocellular carcinoma (HCC) and is typically accompanied by higher levels of serum dipeptidyl peptidase 4 (DPP4). However, the role of DPP4 in obesity-promoted HCC is unclear. Here, we found that consumption of a high-fat diet (HFD) promoted HCC cell proliferation and metastasis and led to poor survival in a carcinogen-induced model of HCC in rats. Notably, genetic ablation of DPP4 or treatment with a DPP4 inhibitor (vildagliptin) prevented HFD-induced HCC. Moreover, HFD-induced DPP4 activity facilitated angiogenesis and cancer cell metastasis in vitro and in vivo, and vildagliptin prevented tumor progression by mediating the pro-angiogenic role of chemokine ligand 2 (CCL2). Loss of DPP4 effectively reversed HFD-induced CCL2 production and angiogenesis, indicating that the DPP4/CCL2/angiogenesis cascade had key roles in HFD-associated HCC progression. Furthermore, concomitant changes in serum DPP4 and CCL2 were observed in 210 patients with HCC, and high serum DPP4 activity was associated with poor clinical prognosis. These results revealed a link between obesity-related high serum DPP4 activity and HCC progression. Inhibition of DPP4 may represent a novel therapeutic intervention for patients with HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
- Author
-
Han, Tao, Xiang, Dai-Min, Sun, Wen, Liu, Na, Sun, Huan-Lin, Wen, Wen, Shen, Wei-Feng, Wang, Ruo-Yu, Chen, Cheng, Wang, Xue, Cheng, Zhuo, Li, Heng-Yu, Wu, Meng-Chao, Cong, Wen-Ming, Feng, Gen-Sheng, Ding, Jin, and Wang, Hong-Yang
- Subjects
- *
LIVER cancer patients , *LIVER cancer , *PROTEIN-tyrosine phosphatase , *GENETIC overexpression , *CANCER invasiveness , *IMMUNOBLOTTING , *PROGNOSIS - Abstract
Background & Aims We have previously reported that Shp2, a tyrosine phosphatase previously known as a pro-leukemogenic molecule, suppresses the initiation of hepatocellular carcinoma (HCC). However, the role of Shp2 in HCC progression remains obscure. Methods Shp2 expression was determined in human HCC using real-time PCR, immunoblotting and immunohistochemistry. Clinical significance of Shp2 expression was analyzed in 301 HCC tissues with clinico-pathological characteristics and follow-up information. Short hairpin RNA was utilized to investigate the function of Shp2 in hepatoma cell behavior. Role of Shp2 in HCC progression was monitored through nude mice xenograft assay. Kinase activity assay and co-immunoprecipitation were used for mechanism analysis. Results Elevated expression of Shp2 was detected in 65.9% (394/598) of human HCCs, and its levels were even higher in metastasized foci. Overexpression of Shp2 correlated well with the malignant clinico-pathological characteristics of HCC and predicted the poor prognosis of patients. Interference of Shp2 expression suppressed the proliferation of hepatoma cells in vitro and inhibited the growth of HCC xenografts in vivo . Down-regulation of Shp2 attenuated the adhesion and migration of hepatoma cells and diminished metastasized HCC formation in mice. Our data demonstrated that Shp2 promotes HCC growth and metastasis by coordinately activating Ras/Raf/Erk pathway and PI3-K/Akt/mTOR cascade. Moreover, down-regulation of Shp2 enhanced the sensitivity of hepatoma cells upon sorafenib treatment, and patients with low Shp2 expression exhibited superior prognosis to sorafenib. Conclusions Shp2 promotes the progression of HCC and may serve as a prognostic biomarker for patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer.
- Author
-
Zhang, Yang, Guan, Dong-xian, Shi, Jie, Gao, Hong, Li, Jing-jing, Zhao, Jiang-sha, Qiu, Lin, Liu, Jiang, Li, Nan, Guo, Wei-xing, Xue, Jie, Zhou, Fei-guo, Wu, Meng-chao, Wang, Hong-yang, Xie, Dong, and Cheng, Shu-qun
- Subjects
- *
CANCER cell differentiation , *LIVER cancer , *TRETINOIN , *CANCER chemotherapy , *CISPLATIN , *LIVER cancer patients , *ADJUVANT treatment of cancer - Abstract
Background & Aims: Systemic chemotherapy serves as an adjuvant treatment for post-operation patients with hepatocellular carcinoma (HCC), and provides curative option for the patients with unresectable HCC. However, its efficiency is largely limited because of the high incidence of chemo-resistance. Increasing evidence has shown that tumor initiating cells (TICs) not only have the ability to self-renew and drive the initiation and progression of cancer, but also exhibit greater resistance to conventional chemo- and radio-therapies than non-TICs. It was the aim of this study to investigate the effects of ATRA with and without cisplatin on TIC differentiation and apoptosis in human HCC. Methods: In the present study, we evaluated the TICs of HCC cell differentiation induced by all-trans retinoic acid (ATRA), and developed a novel chemotherapeutic approach to HCC, by characterizing the function of combinatorial treatment with cis-diammineplatinum(II) (cisplatin) and ATRA in vitro and in vivo. Results: ATRA effectively induced differentiation of TICs, which potentiated the cytotoxic effects of cisplatin. The combinatorial treatment of ATRA acid and cisplatin reduced protein kinase B (AKT) (Thr308) phosphorylation, and promoted apoptosis of HCC cells more significantly than treatment with cisplatin alone. In addition, the combined treatment with the two drugs exerted stronger inhibition on either HCC cell migration in vitro or metastasis in vivo, when compared to the treatment with either drug alone. Conclusions: These results indicated that ATRA could significantly improve the effect of cisplatin, which is at least partially attributed to ATRA-induced differentiation of HCC TICs, and the subsequent decrease in this chemo-resistant subpopulation. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
8. TGF-β-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma
- Author
-
Yang, Pengyuan, Li, Qi-Jing, Feng, Yuxiong, Zhang, Yun, Markowitz, Geoffrey J., Ning, Shanglei, Deng, Yuezhen, Zhao, Jiangsha, Jiang, Shan, Yuan, Yunfei, Wang, Hong-Yang, Cheng, Shu-Qun, Xie, Dong, and Wang, Xiao-Fan
- Subjects
- *
TRANSFORMING growth factors , *HEPATITIS B virus , *LIVER cancer , *VIRUS diseases , *MICRORNA genetics , *CHEMOKINES , *METASTASIS - Abstract
Summary: Portal vein tumor thrombus (PVTT) is strongly correlated to a poor prognosis for patients with hepatocellular carcinoma (HCC). In this study, we uncovered a causative link between hepatitis B virus (HBV) infection and development of PVTT. Mechanistically, elevated TGF-β activity, associated with the persistent presence of HBV in the liver tissue, suppresses the expression of microRNA-34a, leading to enhanced production of chemokine CCL22, which recruits regulatory T (Treg) cells to facilitate immune escape. These findings strongly suggest that HBV infection and activity of the TGF-β-miR-34a-CCL22 axis serve as potent etiological factors to predispose HCC patients for the development of PVTT, possibly through the creation of an immune-subversive microenvironment to favor colonization of disseminated HCC cells in the portal venous system. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
9. OV6+ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma
- Author
-
Yang, Wen, Wang, Chao, Lin, Yan, Liu, Qiong, Yu, Le-xing, Tang, Liang, Yan, He-Xin, Fu, Jing, Chen, Yao, Zhang, Hui-Lu, Zheng, Long-Yi, He, Ya-Qin, Li, Yu-Qiong, Wu, Fu-Quan, Zou, Shan-Shan, Li, Zhong, Wu, Meng-Chao, Feng, Gen-Sheng, and Wang, Hong-Yang
- Subjects
- *
LIVER cancer , *CANCER invasiveness , *STROMAL cells , *CXCR4 receptors , *REVERSE transcriptase polymerase chain reaction , *KAPLAN-Meier estimator , *METASTASIS - Abstract
Background & Aims: Accumulating evidence suggests the involvement of tumor-initiating cells (T-ICs) in cancer genesis, but whether liver T-ICs contribute to HCC invasion and metastasis remains unclear. Methods: OV6+ T-ICs were isolated from SMMC7721 and HuH7 cell lines by magnetic sorting. Characteristics of T-ICs were assessed by in vitro and mouse xenograft assays. Expression of OV6 was determined by immunostaining in specimens from 218 HCC patients, and Kaplan–Meier survival analysis was used to determine the correlation of OV6 expression with prognosis. Results: OV6+ T-ICs isolated from HCC cell lines not only possess a higher capacity to form tumor spheroids in vitro, but also had a greater potential to form tumors when implanted in non-obese diabetic/severe combined immunodeficient mice, suggesting their elevated self-renewal capacity and tumorigenicity. Moreover, OV6+ T-ICs exhibited more invasive and metastatic potentials both in vitro and in vivo. Patients with more OV6+ tumor cells were associated with aggressive clinicopathologic features and poor prognosis. CXCR4 is expressed at higher levels in OV6+ cells. Recombinant stromal cell-derived factor-1 (SDF-1) treatment expanded the OV6+ HCC T-ICs population, by sustaining the stem cell property of OV6+ cells. The SDF-1 effect was blocked by a specific CXCR4 inhibitor, AMD3100, or transfection of siRNA targeting CXCR4. Conclusions: OV6+ HCC cells may represent a subpopulation of T-ICs with augmented invasion and metastasis potential, which contribute to progression and metastasis of HCC. The SDF-1/CXCR4 axis also provides therapeutic targets for elimination of liver T-ICs. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.